Physician profile
Jose Azarcon
NPI 1285627455
$5,785.33
in general payments reported to CMS, 2019-2025
55 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $408 · 2021: $1,087 · 2022: $994 · 2023: $1,441 · 2024: $1,023 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,653.03 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $327.93 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $315.75 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $286.02 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $271.64 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $239.69 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Janssen Pharmaceuticals, INC | $173.01 | 2019-2024 | Spravato |
| Pfizer INC. | $170.28 | 2019-2025 | |
| Viiv Healthcare Company | $165.79 | 2022-2024 | Apretude |
| Abbott Laboratories | $143.64 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Gilead Sciences, INC. | $138.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.27 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $122.52 | 2021 | |
| Genentech USA, INC. | $120.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.46 | 2020-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Azarcon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.